Drug Profile
Research programme: ocular disorder therapeutics - Surface Ophthalmics
Alternative Names: SURF-300Latest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator Harrow Health
- Developer Surface Ophthalmics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders